Holen Sie sich die Stockscreener-App
1.415
16.94%
0.205
Schlusskurs vom Vortag:
$1.21
Offen:
$1.21
24-Stunden-Volumen:
743.88K
Relative Volume:
1.43
Marktkapitalisierung:
$63.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-71.17M
KGV:
-1.018
EPS:
-1.39
Netto-Cashflow:
$-70.97M
1W Leistung:
+43.77%
1M Leistung:
+52.74%
6M Leistung:
-67.55%
1J Leistung:
-69.57%
1-Tages-Spanne:
$1.18
$1.43
1-Wochen-Bereich:
$0.9326
$1.43
52-Wochen-Spanne:
$0.721
$6.24
Inozyme Pharma Inc Stock (INZY) Company Profile
Firmenname
Inozyme Pharma Inc
Sektor
Branche
Telefon
857-330-4340
Adresse
321 SUMMER STREET, BOSTON
Vergleichen Sie INZY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
1.41 | 63.23M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.65 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.21 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
651.03 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.10 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.53 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Eingeleitet | Raymond James | Outperform |
| 2024-09-12 | Eingeleitet | Stifel | Buy |
| 2024-08-13 | Fortgesetzt | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2022-05-26 | Eingeleitet | Jefferies | Hold |
| 2022-02-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-29 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten
JPMorgan Chase & Co. Acquires 99,944 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc’s Shares Reel: -19.01% Quarterly Revenue Decline Amid 73.87M Market Cap - investchronicle.com
INZY Stock Sees Surge of Approximately 17.28% in Last Five Days - knoxdaily.com
Are Inozyme Pharma Inc’shares a good deal? - uspostnews.com
Eventide Asset Management, LLC Reduces Stake in Inozyme Pharma I - GuruFocus
Renaissance Technologies LLC Buys 256,599 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc [NASDAQ: INZY] Sees Decrease in Stock Value - knoxdaily.com
Financial Snapshot: Analyzing Inozyme Pharma Inc (INZY)’s Key Ratio Metrics - DWinneX
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Is Now A Good Time To Invest In Inozyme Pharma Inc (NASDAQ: INZY)? - Stocksregister
Wellington Management Group LLP Lowers Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Raymond James Financial Inc. Invests $205,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
H.C. Wainwright maintains Buy on Inozyme stock with $16 target By Investing.com - Investing.com India
H.C. Wainwright maintains Buy on Inozyme stock with $16 target - Investing.com
Inozyme Pharma (INZY) Publishes Comprehensive Study on ENPP1 Def - GuruFocus
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Rea - GuruFocus
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency - The National Law Review
INZY stock touches 52-week low at $0.77 amid market challenges - Investing.com UK
Rare Disease Innovator Inozyme Pharma Reveals Latest Progress at Elite Healthcare Conference - Stock Titan
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Inozyme Pharma Inc (NASDAQ: INZY) Has Decreased By -82.88 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline By Investing.com - Investing.com South Africa
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline - Investing.com Australia
FY2027 EPS Estimates for Inozyme Pharma Raised by Analyst - Defense World
Raymond James Issues Pessimistic Forecast for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush - Defense World
Q1 EPS Estimates for Inozyme Pharma Reduced by HC Wainwright - Defense World
Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - insights.citeline.com
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $15.00 at Needham & Company LLC - Defense World
Inozyme Pharma’s (INZY) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Piper Sandler cuts Inozyme Pharma stock target to $23 By Investing.com - Investing.com Australia
Inozyme Pharma stock hits 52-week low at $1.03 amid sharp decline - Investing.com
Piper Sandler cuts Inozyme Pharma stock target to $23 - Investing.com
Inozyme Pharma Focuses on ENPP1 Deficiency Program - TipRanks
Inozyme Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating - Marketscreener.com
Inozyme reports prioritization of ENPP1 Deficiency program, workforce reduction - TipRanks
Inozyme Pharma Reports 2024 Financial Results and Strategic Prioritization of ENPP1 Deficiency Program - Nasdaq
Inozyme Pharma, Inc. SEC 10-K Report - TradingView
Form 10-K Inozyme Pharma, Inc. For: Dec 31 - StreetInsider
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization ... - Bluefield Daily Telegraph
Finanzdaten der Inozyme Pharma Inc-Aktie (INZY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
2.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):